Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myogenic progenitor cell (induced pluripotent stem cell-derived) (iPSC-derived myogenic progenitor cell (iMP))
- Target
- iPSC-derived myogenic progenitor cell (iMP)
- Molecular classification
- Other (Cellular therapy/Progenitor cell)
01
Overview
Myogenic progenitor cells derived from induced pluripotent stem cells (iPSC-derived myogenic progenitor cells, iMPs) are a specialized cell type generated in vitro with the capacity to engraft and regenerate damaged skeletal muscle tissue. These cells—often identified by expression of adult muscle stem cell markers such as Pax7—are developed via direct differentiation protocols from pluripotent stem cells, involving modulation of Wnt and BMP signaling pathways. iMPs represent a promising therapy for diseases such as Duchenne muscular dystrophy and traumatic muscle injuries, as they demonstrate robust engraftment, myogenic differentiation, and potential immunological tolerance. Key challenges for therapeutic use include achieving functional maturity, avoiding tumorigenicity, and ensuring immune compatibility[1][2][3][4][5].
- Other names
- iPSC-derived myogenic progenitor cellMyogenic precursor cell (iPSC-derived)Induced myogenic progenitor (iMP)Pluripotent stem cell-derived myogenic progenitor
02
Mechanism of action
Direct cell replacement (regenerating muscle fibers by differentiation into myocytes/myotubes); Paracrine effects (potential stimulation of endogenous repair)
03
Biological functions
Skeletal muscle regenerationCell differentiationCell proliferationTissue repair
04
Disease associations
Muscular dystrophyMuscle injury and traumaCongenital myopathies
05
Safety considerations
Tumorigenic potential (risk from residual undifferentiated iPSCs)Immunogenicity/Immune responseIncomplete functional integration or immaturity of engrafted cellsOff-target tissue formation or fibrosis
06
Biomarkers
Pax7 (adult muscle stem cell marker)CD271, ERBB3 (cell surface markers for enrichment)Desmin, MyoD, Myogenin (differentiation markers)
Beyond the preview
Go deeper on Myogenic progenitor cell (induced pluripotent stem cell-derived) (iPSC-derived myogenic progenitor cell (iMP)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myogenic progenitor cell (induced pluripotent stem cell-derived) (iPSC-derived myogenic progenitor cell (iMP)).